Literature DB >> 31400851

Benzyloxycarbonyl-proline-prolinal (ZPP): Dual complementary roles for neutrophil inhibition.

D W Russell1, M Hardison2, K R Genschmer2, T Szul3, P E Bratcher4, M Abdul Roda5, X Xu6, L Viera7, J E Blalock8, A Gaggar9, B D Noerager10.   

Abstract

Neutrophil influx and activation contributes to organ damage in several major lung diseases. This inflammatory influx is initiated and propagated by both classical chemokines such as interleukin-8 and by downstream mediators such as the collagen fragment cum neutrophil chemokine Pro-Gly-Pro (PGP), which share use of the ELR + CXC receptor family. Benzyloxycarbonyl-proline-prolinal (ZPP) is known to suppress the PGP pathway via inhibition of prolyl endopeptidase (PE), the terminal enzyme in the generation of PGP from collagen. However, the structural homology of ZPP and PGP suggests that ZPP might also directly affect classical glutamate-leucine-arginine positive (ELR+) CXC chemokine signaling. In this investigation, we confirm that ZPP inhibits PE in vitro, demonstrate that ZPP inhibits both ELR + CXC and PGP-mediated chemotaxis in human and murine neutrophils, abrogates neutrophil influx induced by murine intratracheal challenge with LPS, and attenuates human neutrophil chemotaxis to sputum samples of human subjects with cystic fibrosis. Cumulatively, these data demonstrate that ZPP has dual, complementary inhibitory effects upon neutrophil chemokine/matrikine signaling which make it an attractive compound for clinical study of neutrophil inhibition in conditions (such as cystic fibrosis and chronic obstructive pulmonary disease) which evidence concurrent harmful increases of both chemokine and matrikine signaling.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Benzyloxycarbonyl-proline-prolinal; COPD; CXCR; PGP; Prolyl-endopeptidase; ZPP

Mesh:

Substances:

Year:  2019        PMID: 31400851      PMCID: PMC6730661          DOI: 10.1016/j.bbrc.2019.07.111

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  40 in total

Review 1.  Neutrophils and immunity: challenges and opportunities.

Authors:  Carl Nathan
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

2.  Neutrophilic inflammation and IL-8 levels in induced sputum of alpha-1-antitrypsin PiMZ subjects.

Authors:  M Malerba; F Ricciardolo; A Radaeli; C Torregiani; L Ceriani; E Mori; M Bontempelli; C Tantucci; V Grassi
Journal:  Thorax       Date:  2005-11-11       Impact factor: 9.139

3.  Lipopolysaccharide-induced lung injury in mice. I. Concomitant evaluation of inflammatory cells and haemorrhagic lung damage.

Authors:  C Asti; V Ruggieri; S Porzio; R Chiusaroli; G Melillo; G F Caselli
Journal:  Pulm Pharmacol Ther       Date:  2000       Impact factor: 3.410

Review 4.  Mechanisms in COPD: differences from asthma.

Authors:  P J Barnes
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

5.  Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis.

Authors:  Florencia McAllister; Adam Henry; James L Kreindler; Patricia J Dubin; Lauren Ulrich; Chad Steele; Jonathan D Finder; Joseph M Pilewski; Beatriz M Carreno; Samuel J Goldman; Jaana Pirhonen; Jay K Kolls
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

6.  Evidence that prolyl endopeptidase participates in the processing of brain angiotensin.

Authors:  W R Welches; R A Santos; M C Chappell; K B Brosnihan; L J Greene; C M Ferrario
Journal:  J Hypertens       Date:  1991-07       Impact factor: 4.844

7.  Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study.

Authors:  Donald A Mahler; Saling Huang; Mohammad Tabrizi; Gregory M Bell
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

8.  A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation.

Authors:  Nathaniel M Weathington; Anneke H van Houwelingen; Brett D Noerager; Patricia L Jackson; Aletta D Kraneveld; F Shawn Galin; Gert Folkerts; Frans P Nijkamp; J Edwin Blalock
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

9.  Expression of macrophage inflammatory protein-2 and KC mRNA in pulmonary inflammation.

Authors:  S Huang; J D Paulauskis; J J Godleski; L Kobzik
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

10.  Characterization of a novel chemotactic factor for neutrophils in the bronchial secretions of patients with cystic fibrosis.

Authors:  Tecla S Dudez; Marc Chanson; Susanna E Schlegel-Haueter; Susanne Suter
Journal:  J Infect Dis       Date:  2002-08-28       Impact factor: 5.226

View more
  2 in total

Review 1.  The Neutrophil: Constant Defender and First Responder.

Authors:  Noah Fine; Nikola Tasevski; Christopher A McCulloch; Howard C Tenenbaum; Michael Glogauer
Journal:  Front Immunol       Date:  2020-09-24       Impact factor: 7.561

2.  Prolyl endopeptidase contributes to early neutrophilic inflammation in acute myocardial transplant rejection.

Authors:  Gregory A Payne; Nirmal S Sharma; Charitharth V Lal; Chunyan Song; Lingling Guo; Camilla Margaroli; Liliana Viera; Siva Kumar; Jindong Li; Dongqi Xing; Melanie Bosley; Xin Xu; J Michael Wells; James F George; Jose Tallaj; Massoud Leesar; J Edwin Blalock; Amit Gaggar
Journal:  JCI Insight       Date:  2021-03-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.